Evidence supporting the use of: Spirulina
For the health condition: Chronic Obstructive Pulmonary Disorder

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Spirulina, a blue-green algae, has been investigated for its potential benefits in supporting patients with Chronic Obstructive Pulmonary Disease (COPD). Some scientific studies have explored its use due to its antioxidant, anti-inflammatory, and immunomodulatory properties. COPD is characterized by chronic airway inflammation and oxidative stress, and spirulina contains bioactive compounds such as phycocyanin, which have demonstrated the ability to scavenge free radicals and modulate inflammatory pathways in laboratory and animal studies. Limited small-scale human clinical trials have suggested that spirulina supplementation may improve certain parameters in COPD patients, such as reducing oxidative stress markers, improving pulmonary function tests, and enhancing quality of life. For example, a randomized controlled trial published in the journal Respiratory Medicine (2012) found that patients receiving spirulina showed a statistically significant improvement in forced expiratory volume (FEV1) and a reduction in systemic inflammation compared to placebo. However, these studies often have small sample sizes and short durations, and results are not uniformly positive across all research. While the biological plausibility exists, and preliminary data are promising, the overall quality and quantity of evidence is still limited. Thus, spirulina's use in COPD management is supported by early scientific investigations, but more robust, large-scale clinical trials are necessary before it can be routinely recommended. Healthcare professionals should consider the current evidence as preliminary and advise patients accordingly.

More about spirulina
More about Chronic Obstructive Pulmonary Disorder